Fig. 4From: The effects of inhaled aztreonam on the cystic fibrosis lung microbiomeAnalysis of shifts in the microbiome of samples collected prior to the initiation of AZLI (excluding those on systemic antibiotics) taken from responders (R) (n = 35) vs non-responders (NR) (n = 28). a Shannon alpha diversity measures comparing samples from R and NR. b PCoA plot showing community-wide differences of samples taken from R vs NR as measured by Bray-Curtis beta diversity measures. PERMANOVA reveals no significant community-wide differences in aggregate (p = 0.49) or when permutations were constrained by patient (p = 0.85). c–f Box plots showing significant differences in the log abundance of organisms at the OTU level present in >20% of samples taken from R vs NR. Wilcoxon rank-sum tests reveal significant differences in organisms belonging to four distinct OTUsBack to article page